Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence trial of two quetiapine formulations
2026-527162-72-00Phase 2Authorised
- Sponsor
- Laboratorios Alter
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of quetiapine in mental disorder (2 arms), sponsored by Laboratorios Alter. Primary endpoint: Primary pharmacokinetic endpoints. Planned start Sep 2026; status: authorised.
02
Drugs
quetiapine
03
Conditions
mental disorder
Beyond the preview
Go deeper on 2026-527162-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527162-72-00.